Literature DB >> 29884741

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Brian A Walker1, Konstantinos Mavrommatis2, Christopher P Wardell1, T Cody Ashby1, Michael Bauer1, Faith E Davies1, Adam Rosenthal3, Hongwei Wang3, Pingping Qu3, Antje Hoering3, Mehmet Samur4, Fadi Towfic5, Maria Ortiz6, Erin Flynt5, Zhinuan Yu5, Zhihong Yang5, Dan Rozelle7, John Obenauer7, Matthew Trotter6, Daniel Auclair8, Jonathan Keats9, Niccolo Bolli10, Mariateresa Fulciniti4, Raphael Szalat4, Philippe Moreau11, Brian Durie12, A Keith Stewart13, Hartmut Goldschmidt14, Marc S Raab14,15, Hermann Einsele16, Pieter Sonneveld17, Jesus San Miguel18, Sagar Lonial19, Graham H Jackson20, Kenneth C Anderson4, Herve Avet-Loiseau21,22, Nikhil Munshi4, Anjan Thakurta5, Gareth J Morgan1.   

Abstract

Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including IDH1, IDH2, HUWE1, KLHL6, and PTPN11 Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and IRF4; t(14;16) with mutations in MAF, BRAF, DIS3, and ATM; and hyperdiploidy with gain 11q, mutations in FAM46C, and MYC rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29884741      PMCID: PMC6097138          DOI: 10.1182/blood-2018-03-840132

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.

Authors:  David N Boone; Ying Qi; Zhaoliang Li; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 2.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

3.  MYC, MAX, and small cell lung cancer.

Authors:  Charles M Rudin; J T Poirier
Journal:  Cancer Discov       Date:  2014-03       Impact factor: 39.397

4.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Authors:  Florence Magrangeas; Hervé Avet-Loiseau; Nikhil C Munshi; Stéphane Minvielle
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 5.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

6.  Chromoplexy: a new category of complex rearrangements in the cancer genome.

Authors:  Michael M Shen
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

7.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

8.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

9.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

10.  Recurrent inactivating RASA2 mutations in melanoma.

Authors:  Rand Arafeh; Nouar Qutob; Rafi Emmanuel; Alona Keren-Paz; Jason Madore; Abdel Elkahloun; James S Wilmott; Jared J Gartner; Antonella Di Pizio; Sabina Winograd-Katz; Sivasish Sindiri; Ron Rotkopf; Ken Dutton-Regester; Peter Johansson; Antonia L Pritchard; Nicola Waddell; Victoria K Hill; Jimmy C Lin; Yael Hevroni; Steven A Rosenberg; Javed Khan; Shifra Ben-Dor; Masha Y Niv; Igor Ulitsky; Graham J Mann; Richard A Scolyer; Nicholas K Hayward; Yardena Samuels
Journal:  Nat Genet       Date:  2015-10-26       Impact factor: 38.330

View more
  131 in total

Review 1.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

2.  Detailing the genomic landscape of myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

Review 3.  Reconstructing the evolutionary history of multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Eileen M Boyle; Gareth J Morgan
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

Review 4.  The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.

Authors:  Xiaofeng Gong; Danyu Du; Yanran Deng; Yuqi Zhou; Li Sun; Shengtao Yuan
Journal:  Invest New Drugs       Date:  2020-02-01       Impact factor: 3.850

Review 5.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

6.  Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.

Authors:  Yu-Hsiu T Lin; Gregory P Way; Benjamin G Barwick; Margarette C Mariano; Makeba Marcoulis; Ian D Ferguson; Christoph Driessen; Lawrence H Boise; Casey S Greene; Arun P Wiita
Journal:  Blood Adv       Date:  2019-11-12

Review 7.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

8.  Noncoding RNA processing by DIS3 regulates chromosomal architecture and somatic hypermutation in B cells.

Authors:  Brice Laffleur; Junghyun Lim; Wanwei Zhang; Yiyun Chen; Evangelos Pefanis; Jonathan Bizarro; Carolina R Batista; Lijing Wu; Aris N Economides; Jiguang Wang; Uttiya Basu
Journal:  Nat Genet       Date:  2021-02-01       Impact factor: 38.330

Review 9.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

10.  High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Authors:  Anjan Thakurta; Maria Ortiz; Pedro Blecua; Fadi Towfic; Jill Corre; Natalya V Serbina; Erin Flynt; Zhinuan Yu; Zhihong Yang; Antonio Palumbo; Meletios A Dimopoulos; Norma C Gutierrez; Hartmut Goldschmidt; Pieter Sonneveld; Herve Avet-Loiseau
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.